Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic mechanisms of motor fluctuations

J I Sage1, M H Mark

  • 1Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick 08903.

Neurology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A controlled trial of antidepressants in patients with Parkinson disease and depression.

Neurology·2008
Same author

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Neurology·2008
Same author

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study.

Neurology·2006
Same author

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.

Neurology·2005
Same author

Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.

Movement disorders : official journal of the Movement Disorder Society·2005
Same author

A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study.

Neurology·2003
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Parkinson's disease patients experience levodopa motor fluctuations due to issues with drug delivery to the brain and receptor interactions. Understanding these pharmacokinetic and pharmacodynamic changes is key to managing treatment response.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Parkinson's disease (PD) patients initially respond well to levodopa.
  • Over time, motor fluctuations and unpredictable responses to levodopa emerge.

Purpose of the Study:

  • To elucidate the mechanisms underlying levodopa-induced motor fluctuations in Parkinson's disease.
  • To categorize these mechanisms into central pharmacokinetics, peripheral pharmacokinetics, and pharmacodynamics.

Main Methods:

  • The study reviews existing literature on levodopa pharmacokinetics and pharmacodynamics in PD.
  • It categorizes the contributing factors to motor fluctuations based on their site of action.

Main Results:

  • Early "wearing-off" is linked to central pharmacokinetic changes, specifically reduced presynaptic dopamine storage.

Related Experiment Videos

  • Later fluctuations may involve peripheral pharmacokinetics (gastric emptying, transport) and central pharmacodynamics (striatal receptor alterations).

    • Conclusions:

    • Motor fluctuations in Parkinson's disease result from a complex interplay of central and peripheral pharmacokinetic factors, as well as pharmacodynamic changes.
    • Understanding these mechanisms is crucial for optimizing levodopa therapy and managing motor complications in PD.